Brief: Trevi Therapeutics Announces Results From Phase 2B/3 Prism Open-Label Extension Study Of Haduvio™ In Prurigo Nodularis
Trevi Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Trevi Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Trevi Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million – SEC Filing
Trevi Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Trevi Therapeutics Announces First Quarter 2023 Financial Results And Provides Business Update
Trevi Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Trevi Therapeutics Announces Fourth Quarter And Year End 2022 Financial Results And Provides Business Update
Trevi Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Trevi Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ncino, Newmont, Seagen
Brief: Trevi Therapeutics Reports Notice Of Allowance For U.S. Patent Application Covering Use Of Haduvio (nalbuphine ER)
Brief: Trevi Therapeutics Provides Business Update Ahead Of Upcoming Conferences
SVB starts Trevi at 'outperform' on cough, itch treatment potential
Trevi Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Trevi Therapeutics Announces Third Quarter 2022 Financial Results And Provides Business Update
Trevi Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Trevi Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Trevi Therapeutics To Present Final Data From Phase 2 Trial Of Oral Nalbuphine Extended Release For Chronic Cough In Ipf At Bts' Winter Meeting